Steglatro

Quote
anonymous said:
Steglatro has been out almost a year. Certainly out of launch mode. What is the market share within the SGLT2 class and how much money is it generating?
Click to expand...

Still not generating as much as we hoped. It is a good product, but there is no real clinical reason to use our product over established products. The low WAC price doesn’t mean a thing to doctors because it doesn’t translate into better coverage for their patients. And they even question the amputation data. It is not an easy sell. And it may never become a money maker in a crowded market. I am close to retirement so I will hang on. There is no way I will walk away without a package at this point. Definitely don’t see it being long before announcements happen.
 


















4th in class , 4th in sales ( nationally) . Competition has CV data and this does make a difference to HCP's . Trying to sell Stegratro by playing defense with no compelling reason to choose over competitors.
 






Steglatro is doing very well in Florida. We have found a way to leverage the many benefits with Steglatro vs the competition and it is paying big dividends in Florida. Merck needs to put the Florida reps on stage and share all we are doing to generate sales. Call a Florida rep in the interim and get the strategy we are employing.
 






Good for you Florida. In my area steglatro is disadvantaged on the major PBM's .
Step edit after failure of 2 SGLT2 competitors. NDC blocked on another. Co pay $30 above other SGLT2 's on another . Impossible!
 












Steglatro is doing very well in a tough market. Management could not be more pleased. It has passed Invokana in most markets and quickly approaching Farxiga. Great selling
 






How is Steglatro doing. Not even mentioned on earnings call today. In fact has never been mentioned on any earnings call. What the fuck. Why has it never been mentioned one time.. Why is Merck even promoting it?
 












anonymous said:
How is Steglatro doing. Not even mentioned on earnings call today. In fact has never been mentioned on any earnings call. What the fuck. Why has it never been mentioned one time.. Why is Merck even promoting it?
Click to expand...
Why is Steglatro never mentioned when Merck reports. Wouldn’t the investment people want to know how a new diabetes drug that Merck is launching is doing considering that Januvia was one of the most successful drugs ever in the diabetes market. How is their new entry doing????????
 
















































anonymous said:
Steglatro is doing very well in a tough market. Management could not be more pleased. It has passed Invokana in most markets and quickly approaching Farxiga. Great selling
Click to expand...
Management is very pleased. Steglatro appears to be heading in the direction of surpassing Januvia sales. Merck management has done a wonderful job with Steglatro and certainly need to be commended. Featured products by year end will be Steglatro and Keytruda
 






anonymous said:
Management is very pleased. Steglatro appears to be heading in the direction of surpassing Januvia sales. Merck management has done a wonderful job with Steglatro and certainly need to be commended. Featured products by year end will be Steglatro and Keytruda
Click to expand...
Steglatro is now overtaking Farxiga in new prescriptions in latest data. Jardiance is very worried about the momentum created with Steglatro
 






Top Bottom
Back
Quote